Welcome to the new scientist and researcher reference section. Your one-stop shop for the essential resources you need to advance your career.
The SNMMI Future Leaders Academy training focuses on setting a clear plan for increasing leadership abilities by developing the necessary skills and organizational expertise to enhance performance and ultimately evolve into a leader both within the nuclear medicine and molecular imaging community and the society.
SNMMI educational programs are designed to meet the professional development needs of scientists involved in nuclear medicine and molecular imaging endeavors.
The most up-to-date and comprehensive source for nuclear medicine coding and reimbursement information on the web. Please note that ALL information and materials within the SNMMI Coding Corner are direct products of the SNMMI Coding and Reimbursement Working Group.
For Hospitals (APCs, IPPS) Find general coding and reimbursement information for hospitals.
For Private Practices (RBRVS) Find general coding and reimbursement information for professionals in private practices.
Coding and Reimbursement Q&A This easy to use feature contains over 100 questions and answers related to topics such as cardiac, endocrine, neurology, nuclear medicine-related drugs, oncology, PET, PET/CT, radiopharmaceuticals, and more!
In nuclear medicine and molecular imaging, small amounts of radioactive agents are administered to the patient to allow the physician to examine molecular processes within the body. These procedures are highly effective, safe and painless diagnostic tools that present physicians with a detailed view of what’s going on inside an individual’s body at the cellular level. For more than 60 years, these studies have been used to evaluate practically all systems within the body, including the heart and brain, as well as to image many types of cancer.
SNMMI has a large body of knowledge in dose optimization that is continually growing and developing. The dose optimization website presents a wide variety of resources, including SNMMI journal articles, educational offerings, media-related information, links to useful websites and more.
The goal of the SNMMI Best Practices in Preclinical Imaging Initiative is to provide guidelines based on the community experience in designing and conducting preclinical imaging experiments.
Available Resources Include:
SNMMI's Center for Molecular Imaging Innovation and Translation is an organizational component within the SNMMI that is dedicated to all aspects of molecular imaging in the detection and management of disease. The center is currently facilitating initiatives to bring molecular imaging discoveries from the lab to the patient and to advance "personalized" medicine.
The Clinical Trials Network’s mission is to advance the use of molecular imaging radiopharmaceuticals in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new agents to regulatory approval. Click here to learn more about the CTN’s Oncology and Neurology Scanner Validation programs, ongoing efforts to harmonize reconstruction parameters in oncology clinical trials, and other services that CTN offers to help scientists advance their research.
The practice guidelines help to identify those elements of the procedure that are most important in obtaining a high-quality examination, while simultaneously controlling costs. Use of standardized procedures will increase the applicability of clinical research among multiple institutions, in turn, increasing the value of research studies, particularly in the field of technology assessment. In the interest of creating strong, comprehensive documents, some guidelines were formally adopted by SNMMI in collaboration with other professional organizations.
An ongoing project of the PET Center of Excellence is the creation of a tracer encyclopedia. In this collection, detailed information regarding various PET tracers and their properties are displayed in easy-to-read charts.
The process of PET reimbursement in the United States has been complex and slowly evolving. The U.S. Food and Drug Administration (FDA) approved the first New Drug Application for 18F-FDG in 1994, in part as a result of efforts led by the Institute for Clinical PET.
PET/CT with Ga-68 DOTATATE has been found to change treatment plans in a majority of patients receiving initial evaluation and subsequent staging of neuroendocrine tumors (NETs).
(MI: Making a Difference)
With more than 30 years of research in radiopharmaceutical chemistry, Silvia Jurisson, a researcher at the University of Missouri, is a world-renowned scientist who continues to develop breakthrough materials used in the detection and treatment of cancer.
SNMMI offers opportunities for nuclear medicine scientists and pharmacists to submit clinical and scientific abstracts to be considered for presentation at upcoming SNMMI conferences and meetings:
SNMMI 2015 Annual Meeting
June 6-10, 2015 in Baltimore, MD, USA
Abstract Submission Deadline: January 12, 2015
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis.
Learn more about journals published by or sponsored by the Society of Nuclear Medicine and Molecular Imaging.
Tools, supported by evidence, to harmonize the practice of nuclear medicine using a progressive and safe approach.